3DBIOTECH Competitors

Stratasys develops industrial grade additive solutions to help you solve critical design and manufacturing challenges, right along your production cycle. Working with you to push the boundaries of what’s possible. And thrive in a changing world. Make additive work for you™.

Biolife, a wholly owned subsidiary of Merit Medical, is medical device company in Sarasota, Florida, that manufactures innovative healthcare and first aid solutions that improve patient care and outcomes. All Biolife products are comprised of a powder with two main ingredients: potassium ferrate and a hydrophilic, or water loving, polymer. StatSeal devices for the healthcare industry are available in both powder and disc form; the disc is made of compressed powder that is encased in a white medical-grade foam. WoundSeal devices for the consumer and occupational health industries are available in powder form. All Biolife devices are manual pressure adjuncts and work via a two-step mechanism of action that occurs simultaneously to form a low pH seal or physical barrier over the wound, protecting it by letting nothing in or nothing out. The hydrophilic polymer rapidly dehydrates the blood and absorbs exudate, stacking up desiccated blood solids beneath to form a seal (scab). The potassium ferrate binds the blood solids and proteins together, adhering the seal (scab) to the wound to stop bleeding and oozing. Beneath the seal, the pH is neutral and blood solids and proteins continue to stack naturally. Above the seal the hydrophilic polymer acts as a desiccant and creates an acidic environment with a pH of ~ 2. All Biolife devices work independently of the clotting cascade to create an occlusive seal over the wound or procedural site, while accelerating hemostasis and helping to improve recovery time. The seal remains over the wound as the body’s healing mechanism begins. As the wound heals, the scab is naturally sloughed off.

Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.